Sow, Samba O; Muhsen, Khitam; Nasrin, Dilruba; Blackwelder, William C; Wu, Yukun; Farag, Tamer H; Panchalingam, Sandra; Sur, Dipika; Zaidi, Anita KM; Faruque, Abu SG; Saha, Debasish; Adegbola, Richard; Alonso, Pedro L; Breiman, Robert F; Bassat, Quique; Tamboura, Boubou; Sanogo, Doh; Onwuchekwa, Uma; Manna, Byomkesh; Ramamurthy, Thandavarayan; Kanungo, Suman; Ahmed, Shahnawaz; Qureshi, Shahida; Quadri, Farheen; Hussain, Anowar; Das, Sumon K; Antonio, Martin; Hossain, M Jahangir; Mandomando, Inacio; Nhampossa, Tacilta; Acacio, Sozinho; Omore, Richard; Oundo, Joseph O; Ochieng, John B; Mintz, Eric D; O'Reilly, Ciara E; Berkeley, Lynette Y; Livio, Sofie; Tennant, Sharon M; Sommerfelt, Halvor; Nataro, James P; Ziv-Baran, Tomer; Robins-Browne, Roy M; Mishcherkin, Vladimir; Zhang, Jixian; Liu, Jie; Houpt, Eric R; Kotloff, Karen L; Levine, Myron M (2016) The Burden ofCryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS). PLOS NEGLICTED TROPICAL DISEASES, 10 (5). ISSN 1935-2735 DOI: https://doi.org/10.1371/journal.pntd.0004729

Downloaded from: http://researchonline.lshtm.ac.uk/4652051/

DOI: 10.1371/journal.pntd.0004729

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE

The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS)

Samba O. Sow, Khitam Muhsen, Dilruba Nasrin, William C. Blackwelder, Yukun Wu, Tamer H. Farag, Sandra Panchalingam, Dipika Sur, Anita K. M. Zaid, Abu S. G. Faruque, Debasish Saha, Richard Adegbola, Pedro L. Alonso, Robert F. Breiman, Quique Bassat, Boubibou Tamboura, Doh Sanogo, Uma Onwuchekwka, Byomkesh Manna, Thandavarayan Ramamurthy, Suman Kanungo, Shahnazaw Ahmed, Shahida Qureshi, Farheen Quadri, Anowar Hossain, Sumon K. Das, Martin Antonio, M. Jahangir Hossain, Inacio Mandomando, Tacilta Nhampossa, Sozinho Acácio, Richard Omore, Joseph O. Oundo, John B. Ochieng, Eric D. Mintz, Ciara E. O’Reilly, Lynette Y. Berkeley, Sofie Livio, Sharon M. Tennant, Halvor Sommerfelt, James P. Nataro, Tamer Ziv-Baran, Roy M. Robins-Browne, Vladimir Mishcherkin, Jixian Zhang, Jie Liu, Eric R. Houp, Karen L. Kotloff, Myron M. Levine.

1 Centre pour le Développement des Vaccins, Bamako, Mali, 2 Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, 3 Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America, 4 Emergent Biosolutions, Gaithersburg, Maryland, United States of America, 5 National Institute of Cholera and Enteric Diseases, Kolkata, India, 6 Department of Paediatrics and Child Health, the Aga Khan University, Karachi, Pakistan, 7 International Centre for Diarrhoeal Disease Research,Mohakhali, Dhaka, Bangladesh, 8 Medical Research Council (United Kingdom) Unit, Fajara, Gambia, 9 GSK Vaccines, Wavre, Belgium, 10 Centro de Investigación en Salud de Mani, Maputo, Mozambique, 11 Instituto Nacional de Saúde, Ministério de Saúde, Maputo, Mozambique, 12 ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic—Universitat de Barcelona, Barcelona, Spain, 13 Global Disease Detection Division, Kenya Office of the US Centers for Disease Control and Prevention, Nairobi, Kenya, 14 Kenya Medical Research Institute/ Centers for Disease Control and Prevention, Kisumu, Kenya, 15 Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America, 16 Centre of Intervention Science in Maternal and Child Health, Centre for International Health, University of Bergen, Bergen, and Department of International Public Health, Norwegian Institute of Public Health, Oslo, Norway, 17 Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel, 18 Department of Microbiology and Immunology, The University of Melbourne, Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, Victoria, Australia, 19 Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, United States of America, 20 Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.

These authors contributed equally to this work.

Copyright: © 2016 Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used within the paper and its Supporting Information files.

Funding: This work was supported by grants 38774 and OPP1033572 from the Bill & Melinda Gates Foundation to MML, URL of the funder’s website: http://www.gatesfoundation.org. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data Availability Statement: All relevant data are available under the Creative Commons CC0 public domain dedication.

Citation: Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. (2016) The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS). PLoS Negl Trop Dis 10(5): e0004729. doi:10.1371/journal.pntd.0004729

OPEN ACCESS

Citation: Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. (2016) The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS). PLoS Negl Trop Dis 10(5): e0004729. doi:10.1371/journal.pntd.0004729

May 2, 2016

Accepted: May 2, 2016

Published: May 24, 2016

Copyright: © 2016 Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used within the paper and its Supporting Information files.

Funding: This work was supported by grants 38774 and OPP1033572 from the Bill & Melinda Gates Foundation to MML, URL of the funder’s website: http://www.gatesfoundation.org. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data Availability Statement: All relevant data are available under the Creative Commons CC0 public domain dedication.

Citation: Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. (2016) The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS). PLoS Negl Trop Dis 10(5): e0004729. doi:10.1371/journal.pntd.0004729

May 2, 2016

Accepted: May 2, 2016

Published: May 24, 2016

Copyright: © 2016 Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used within the paper and its Supporting Information files.

Funding: This work was supported by grants 38774 and OPP1033572 from the Bill & Melinda Gates Foundation to MML, URL of the funder’s website: http://www.gatesfoundation.org. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data Availability Statement: All relevant data are available under the Creative Commons CC0 public domain dedication.

Citation: Sow SO, Muhsen K, Nasrin D, Blackwelder WC, Wu Y, Farag TH, et al. (2016) The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS). PLoS Negl Trop Dis 10(5): e0004729. doi:10.1371/journal.pntd.0004729
Abstract

Background

The importance of Cryptosporidium as a pediatric enteropathogen in developing countries is recognized.

Methods

Data from the Global Enteric Multicenter Study (GEMS), a 3-year, 7-site, case-control study of moderate-to-severe diarrhea (MSD) and GEMS-1A (1-year study of MSD and less-severe diarrhea [LSD]) were analyzed. Stools from 12,110 MSD and 3,174 LSD cases among children aged <60 months and from 21,527 randomly-selected controls matched by age, sex and community were immunoassay-tested for Cryptosporidium. Species of a subset of Cryptosporidium-positive specimens were identified by PCR; GP60 sequencing identified anthropo-notic C. parvum. Combined annual Cryptosporidium-attributable diarrhea incidences among children aged <24 months for African and Asian GEMS sites were extrapolated to sub-Saharan Africa and South Asian regions to estimate region-wide MSD and LSD burdens. Attributable and excess mortality due to Cryptosporidium diarrhea were estimated.

Findings

Cryptosporidium was significantly associated with MSD and LSD below age 24 months. Among Cryptosporidium-positive MSD cases, C. hominis was detected in 77.8% (95% CI, 73.0%-81.9%) and C. parvum in 9.9% (95% CI, 7.1%-13.6%); 92% of C. parvum tested were anthropo-notic genotypes. Annual Cryptosporidium-attributable MSD incidence was 3.48 (95% CI, 2.27–4.67) and 3.18 (95% CI, 1.85–4.52) per 100 child-years in African and Asian infants, respectively, and 1.41 (95% CI, 0.73–2.08) and 1.36 (95% CI, 0.66–2.05) per 100 child-years in toddlers. Corresponding Cryptosporidium-attributable LSD incidences per 100 child-years were 2.52 (95% CI, 0.33–5.01) and 4.88 (95% CI, 0.82–8.92) in infants and 4.04 (95% CI, 0.56–7.51) and 4.71 (95% CI, 0.24–9.18) in toddlers. We estimate 2.9 and 4.7 million Cryptosporidium-attributable cases annually in children aged <24 months in the sub-Saharan Africa and India/Pakistan/Bangladesh/Nepal/Afghanistan regions, respectively, and ~202,000 Cryptosporidium-attributable deaths (regions combined). ~59,000 excess deaths occurred among Cryptosporidium-attributable diarrhea cases over expected if cases had been Cryptosporidium-negative.

Conclusions

The enormous African/Asian Cryptosporidium disease burden warrants investments to develop vaccines, diagnostics and therapies.

Author Summary

Cryptosporidium is a protozoan that causes diarrhea and malnutrition in young children in developing countries, and is associated with diarrhea cases and outbreaks in developed
to date, limited information exists on the burden of Cryptosporidium diarrheal disease in sub-Saharan Africa and South Asia, where most diarrheal disease deaths occur. We estimated the burden of Cryptosporidium-diarrhea and associated deaths in these regions using data from the Global Enteric Multicenter Study (GEMS). Cryptosporidium was associated with diarrhea mainly in children aged <24 months. Infections began in the first few months of life but clinical episodes of Cryptosporidium-associated diarrhea illness peaked at age 6–11 months. The annual number of Cryptosporidium-attributable diarrhea episodes was estimated at 2.9 and 4.7 million in children aged <24 months in sub-Saharan Africa and in the India/Pakistan/Bangladesh/Afghanistan/Nepal region of South Asia, respectively. In both regions combined, Cryptosporidium is estimated to contribute to approximately 202,000 deaths per year, and to ~59,000 more deaths in Cryptosporidium-attributable cases than if those cases had been negative for Cryptosporidium. Our study highlights the enormous burden attributable to Cryptosporidium in Africa and Asia, which underscores the need for developing vaccines and treatments to reduce this burden.

Introduction

Cryptosporidium, the highly infectious protozoan that causes diarrhea in immunocompetent and immunocompromised subjects [1–4], is transmitted via contaminated water or food [1,3,5], swimming or bathing in surface waters [1,3] and by direct person-to-person contact [6], particularly in developing country settings of suboptimal sanitation and limited access to safe drinking water [1,3,4]. Clinical cryptosporidiosis ranges from self-limited mild diarrhea (most commonly) to more severe forms such as persistent diarrhea (lasting 14 days or more) leading to malnutrition, hospitalizations and even death [1,2,5,7–13]. Immunocompromised hosts, e.g., persons with HIV/AIDS and malnourished children in developing countries, are more prone to develop severe clinical illness [1,14]. Fecal shedding of Cryptosporidium oocysts can persist for weeks after clinical illness resolves [15,16]. Since Cryptosporidium oocysts tolerate chlorination, waterborne outbreaks also occur in industrialized countries [1,3,5].

Recently, the Global Enteric Multicenter Study (GEMS) elucidated the relative importance of Cryptosporidium versus many other enteropathogens as a cause of medically-attended diarrhea in young children in developing countries of sub-Saharan Africa (SSA) and South Asia [10], where most young child diarrheal deaths occur. Cryptosporidium was the second leading cause (5–15%) of moderate-to-severe diarrhea (MSD) in infants at all 7 GEMS study sites. Cryptosporidium remained a leading cause of MSD in toddlers age 12–23 months, ranking third after rotavirus and Shigella; 5–9% of all MSD cases in 5 of the 7 sites were attributable to Cryptosporidium [10]. Cryptosporidium-associated MSD negatively impacted linear growth and significantly increased the risk of death in toddlers [10]. A follow-on study, GEMS-1A, investigated Cryptosporidium in association with less-severe diarrhea (LSD) over a 1-year period in 6 of 7 GEMS sites; the LSD cases enrolled in GEMS-1A, like the MSD cases enrolled in GEMS, were pediatric patients who were brought to health care facilities.

We extrapolated GEMS site-specific burdens of Cryptosporidium-associated MSD and LSD in children age <24 months to estimate Cryptosporidium-associated diarrhea burdens for the entire SSA region (except the Republic of South Africa) and the India/Pakistan/Bangladesh/Nepal/Afghanistan (I/P/B/N/A) region of South Asia, where ~80% of global young child deaths due to diarrheal disease occur [17,18].
Methods

Study design and population

GEMS was a prospective matched case-control study conducted for 36 months at 7 sites where demographic surveillance systems (DSS) regularly updated censused populations. Sites included: Basse, The Gambia; Bamako, Mali; Manhiça, Mozambique; Siaya County, Kenya; Kolkata, India; Mirzapur, Bangladesh; and Bin Qasim Town, Pakistan. The published rationale [19], working assumptions [20], epidemiological [21], laboratory [22], and statistical methods [23] of GEMS are summarized below.

The GEMS sampling frame comprised children age <60 months residing within each site’s DSS area. Children brought to sentinel health centers (SHCs) serving each DSS were assessed for criteria for MSD (*vide infra*). Every fortnight, 8–9 cases were targeted for enrollment, per age stratum (0–11, 12–23 and 24–59 months), per site. Within 14 days of each case enrolled, we undertook to enroll 1–3 randomly selected age- and sex-matched controls from the same or nearby communities. MSD was defined as a new acute diarrheal episode (>3 loose stools in the previous 24 hours, occurring after ≥7 diarrhea-free days, and beginning within the previous 7 days), and having some or severe dehydration, initiation of intravenous rehydration based on a clinician’s judgment, visible blood in stools (dysentery), or hospitalization for diarrhea or dysentery. At enrollment, a standardized evaluation, anthropometric measurements, and a stool sample were obtained from cases and controls. A single follow-up home visit was carried out ~60 (range 49–91) days after enrollment, during which the vital status of cases and controls was recorded and anthropometric measurements were made.

GEMS-1A was a 1-year extension in which children with MSD and LSD were enrolled at the SHCs in 6 of 7 GEMS sites, while in Kenya only MSD cases were enrolled. LSD was defined as a new acute diarrhea case seen at SHCs that did not meet the definition of MSD. Data collection methods, including the ~60-day follow-up household visit, were otherwise identical to GEMS.

Laboratory procedures

Case and control stool samples were tested for numerous enteropathogens [10,22], including *Cryptosporidium*, which was detected using an enzyme immunoassay (EIA) (TechLab, Inc. Blacksburg, VA). A random subset of stool specimens from 3,809 GEMS MSD case-control pairs from across all sites was also tested for various enteropathogens using TaqMan Array Card (TAC)-based real-time polymerase chain reaction (PCR). Briefly, nucleic acid was extracted from stool specimens using the QIAamp Fast Stool DNA Mini kit (Qiagen, Valencia, CA). The TaqMan Array Card methodology compartmentalizes PCR reactions for 48 targets per specimen as previously described [24]. For this project we included primers to amplify the 18S rRNA gene of *Cryptosporidium* species [24] and primers for alleles of the LIB13 locus that differentiates *C. hominis* from *C. parvum* [25]. The LIB13 locus is not known to be present in other *Cryptosporidium* species, other than a divergent sequence in *C. cuniculus* (GU327781). The assay did not amplify genomic DNA from *C. meleagridis* isolate TU1867. Specimens with cycle threshold (CT) values ≤40 were considered positive with the species identification assay. For specimens that did not yield a LIB13 result, we performed nested amplification of a longer fragment of the 18S gene rRNA [26], as well as GP60 to try to identify the species [27]. GP60 sequencing was also performed to subtype the available *C. parvum* and *C. hominis* specimens.

Estimating the burden attributable to *Cryptosporidium*

Since *Cryptosporidium* was incriminated as a cause of MSD and LSD mainly among children aged <24 months [10], disease burden extrapolations focused on infants 0–11 and toddlers...
12–23 months of age. Details of the analysis are presented in Fig 1. For each site and age group, pathogen-specific attributable fractions (AFs), weighted according to calendar time and presence or absence of dysentery and adjusted for the presence of other pathogens, and annual attributable incidence (AI) rates for MSD during the 3 years of GEMS have been reported [10]. Employing similar methodology [10,23,28], GEMS-1A data were used to estimate *Cryptosporidium*-attributable incidence of LSD, for site/age groups in which *Cryptosporidium* was associated with LSD with P<0.1 after adjustment for other pathogens. Data from GEMS and GEMS-1A were used to estimate odds ratios (ORs) for *Cryptosporidium* and MSD by 6-month age interval for children aged 0–23 months; weighting by time or presence of dysentery should have little effect on associations with *Cryptosporidium*, and it was not employed in this analysis.

*Cryptosporidium*-specific AFs and AI rates, healthcare utilization rates for MSD and LSD, along with population estimates for the sites, were used to calculate overall *Cryptosporidium*-specific MSD and LSD AI rates separately for the 4 African sites (3 sites for LSD) and 3 Asian sites. These AI rates were extrapolated to the countries where GEMS sites were located, the 51 countries of the SSA region (excluding Republic of South Africa), and the India/Pakistan/Bangladesh/Nepal/Afghanistan (I/P/B/N/A) region of South Asia. For each country or region, the *Cryptosporidium* AI rate was multiplied by the total population (per United Nations estimates) [29] to generate national and region-wide estimates of annual *Cryptosporidium*-attributable MSD and LSD cases. Since GEMS and GEMS-1A were conducted over 5 calendar years, we used the average UN estimated population size (for each GEMS country and region) of children 0–4 years of age during 2005–2010; we divided by 5 to estimate the number of children aged 0–11 and aged 12–23 months. To estimate 95% confidence intervals (CIs), we took the 2.5th and 97.5th percentiles of the number of *Cryptosporidium*-attributable diarrhea cases from 100,000 Monte Carlo simulations, assuming normal distributions for relevant parameters, with standard deviations estimated from Taylor series approximations. The proportions of *C. hominis* and *C. parvum* among the subset of cases (by PCR) were multiplied by the total number of *Cryptosporidium*-attributable diarrhea cases to estimate the species-specific attributable burdens.

### Two strategies to estimate deaths among *Cryptosporidium*-associated diarrhea cases

The number of deaths among children aged <24 months with *Cryptosporidium*-associated diarrhea over the ~60-day follow-up period following enrollment provided an extended case fatality risk (ECFR) [10,21]. However, because GEMS and GEMS-1A were conducted in populations with high or moderate <5 years mortality, and given numerous risk factors for death among children with MSD or LSD, some proportion of deaths among *Cryptosporidium*-associated diarrhea cases would have occurred unrelated to *Cryptosporidium* infection. Accordingly, we utilized two different analytical strategies to estimate more specifically the role of *Cryptosporidium* in deaths of children with *Cryptosporidium*-associated diarrheal illness.

#### *Cryptosporidium*-attributable deaths among *Cryptosporidium*-positive diarrhea cases in the population age <24 months

First, we estimated the *Cryptosporidium*-attributable ECFR by subtracting the extended fatality risk (EFR) over the ~60-day observation period in GEMS/GEMS-1A controls from the ECFR in *Cryptosporidium*-positive cases. We used deaths in all controls, because the numbers of deaths among matched controls of *Cryptosporidium*-positive cases were very small. Multiplying the *Cryptosporidium*-attributable ECFR by the estimated number of *Cryptosporidium*
Cryptosporidium Diarrheal Disease Burden

Cryptosporidium data sources

Demographic surveillance systems (DSS) -- provided accurate population denominators. Health care utilization and attitudes surveys (HUAS) - provided estimates of the proportion of pediatric cases occurring within each site’s DSS, by age group, that were taken to sentinel health centers (SHC) where GEMS recruitment and enrollment were underway.

Enrollment of MSD cases and controls -- 4-years of data from 7 sites during GEMS-1 and GEMS-1A.

Enrollment of LSD cases and controls -- 1-year of data from 6 sites during GEMS-1A.

The adjusted ORs for Cryptosporidium were calculated using conditional logistic regression models by site and age groups [10]. The adjusted AF for Cryptosporidium were calculated by site and age groups [10,23]. The annual mean number of eligible MSD cases at each site and age group was calculated [10,21]. The proportion of all DSS children with diarrhea in each age group that were taken to the GEMS SHCs (“r”) was estimated using data from the HUAS at each site for each age group [10,21,23,28]. The annual number of MSD cases in each age group attributable to Cryptosporidium in the DSS at each site was calculated [10,23]. The annual incidence of MSD attributable to Cryptosporidium by site and age group was calculated [10,23]. The same analyses were performed for LSD.

The annual incidence rates of MSD and LSD attributable to Cryptosporidium, by age group, for the 4 African sites combined (for LSD, 3 sites) were estimated by summing the site-specific numbers of Cryptosporidium-attributable cases per year and then dividing by the total pooled DSS population at the African sites (current study).

Cryptosporidium-attributable MSD and LSD incidence rates were estimated similarly for the Asian sites (current study).

Extrapolations (current study)

The combined incidence rate of the 4 African sites was applied to each African GEMS country individually. The combined incidence rate of the 3 Asian sites was applied to each Asian GEMS country individually.

The combined incidence rate of the 4 African sites was applied to all of the countries of SSA [29]* The combined incidence rate of the 3 Asian sites was applied to the 5 populous South Asian countries I/P/B/N/A [29]*

The population estimates for children aged 0-59 months for each country and the 2 regions obtained from United Nations Population Division [24] were divided by 5 to derive the estimated population of children aged 0-11 and 12-23 months.

The total annual number of Cryptosporidium-attributable cases in each age group was estimated by multiplying the combined incidence rate for each region by the total pooled population in each age group of the countries in the region.

Separate extrapolations were done for LSD and MSD burdens, using the corresponding parameters obtained in the previous steps. The total annual number of Cryptosporidium-attributable cases was estimated by summing the annual numbers of Cryptosporidium-attributable LSD and MSD cases.

Monte Carlo simulations with 100,000 repetitions were performed to estimate the 2.5th and 97.5th percentiles (corresponding to 95% confidence intervals) of the estimated number of cases attributable to Cryptosporidium in each age group/country and region.

We applied the proportions of C. hominis and C. parvum among the cases to the total annual numbers of Cryptosporidium-attributable diarrhea cases to estimate the species-specific burdens.

Two strategies to estimate Cryptosporidium’s role in deaths among Cryptosporidium-associated MSD and LSD cases age <24 months

Cryptosporidium-attributable deaths among Cryptosporidium-positive diarrhea cases in the population

The deaths among children aged <24 months with Cryptosporidium-associated diarrhea over the ~60-day follow-up period post-enrollment provided an extended case fatality risk (ECFR) [10,23]. We estimated the Cryptosporidium-attributable ECFR by subtracting the extended fatality risk (EFR) over the ~60-day observation period in GEMS controls from the ECFR in Cryptosporidium-positive cases (using deaths in all controls). Multiplying the Cryptosporidium-attributable ECFR by the number of Cryptosporidium-positive MSD and LSD cases in the region (SSA or I/P/B/N/A) provided a regional estimate of Cryptosporidium-attributable deaths.

Excess deaths among Cryptosporidium-attributable MSD and LSD cases

We estimated the excess ECFR in Cryptosporidium-positive MSD and LSD cases relative to the ECFR in Cryptosporidium-negative MSD and LSD cases by subtracting the ECFR in Cryptosporidium-negative cases from the ECFR in Cryptosporidium-positive cases. This Cryptosporidium-related excess ECFR was multiplied by the number of Cryptosporidium-attributable cases in each region to estimate excess deaths among Cryptosporidium-attributable cases compared to the expected number of deaths if these diarrhea cases had been negative for Cryptosporidium.
positive MSD and LSD cases in the region (SSA or I/P/B/N/A) provides a regional estimate of *Cryptosporidium*-attributable deaths.

### Excess deaths among *Cryptosporidium*-attributable MSD and LSD cases

We estimated the excess ECFR in *Cryptosporidium*-positive MSD and LSD cases relative to the ECFR in *Cryptosporidium*-negative cases by subtracting the ECFR in *Cryptosporidium*-negative cases from the ECFR in *Cryptosporidium*-positive cases. This excess risk represents the contribution of *Cryptosporidium* to death risk beyond both the background risk of death in the general pediatric population and that of diarrhea patients. The excess ECFR was then multiplied by the number of *Cryptosporidium*-attributable cases in each region, to estimate excess deaths among *Cryptosporidium*-attributable cases compared to the expected number of deaths if these cases had been *Cryptosporidium*-negative.

Estimates of *Cryptosporidium*-related deaths for the combined age group 0–23 months were calculated separately for MSD and LSD for the SSA region, given the much higher ECFR in children with MSD; deaths were estimated for MSD and LSD combined for the I/P/B/N/A region. Two-sided 95% CIs for differences in death risks were estimated by the Miettinen and Nurminen likelihood score method [30]. CIs for numbers of deaths were estimated assuming normal distributions for numbers of deaths, with variances estimated from Taylor series approximations.

Statistical significance was defined as a two-sided P-value < 0.05. Analyses were performed using SAS version 9, IBM SPSS version 22, and NCSS 8.

### Ethical approval

The study protocol was approved by ethics committees at the University of Maryland, Baltimore and at each field site [21]. Parents/caregivers of participants provided written informed consent, and a witnessed consent was obtained for illiterate parents/caretakers.

### Results

#### Patterns of infection and diarrheal illness associated with *Cryptosporidium*, by age

Among 15,284 cases (12,110 MSD and 3,174 LSD) and 21,527 matched controls from GEMS-1 and GEMS-1A, *Cryptosporidium* data were missing for 11 cases (0.07%) and 10 controls (0.0046%) and these participants were excluded from analyses. Among the total 15,284 MSD and LSD cases, six (0.039%) had four matched controls rather than a maximum of three; these six deviations occurred in one African site during GEMS-1. The six extra matched controls were not censured from the dataset. Overall, *Cryptosporidium* was detected in stools from 1632 cases (10.7%) and 1184 controls (5.5%) (P < 0.001); positivity was significantly higher in MSD cases than matched controls in the age groups 0–11 and 12–23 months at all sites, and among the 24–59 month age group in Kenya. *Cryptosporidium* was also significantly more common in LSD cases than controls aged 0–11 and 12–23 months in Gambia and India, while in Mali and...
Table 1. Cryptosporidium positivity (by EIA) in cases and controls by age, site, and severity of diarrhea.

| MSD          | Basse, The Gambia | Bamako, Mali | Manhiça, Mozambique | Siaya County, Kenya | Kolkata, India | Mirzapur, Bangladesh | Karachi, Pakistan |
|--------------|-------------------|--------------|---------------------|--------------------|---------------|----------------------|------------------|
|              | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls |
| Total number (age 0–11 months) | 520 | 783 | 961 | 961 | 439 | 883 | 829 | 896 | 878 | 892 | 672 | 1122 |
| Cryptosporidium (%) | 16.0 | 6.3* | 16.6 | 6.9* | 19.8 | 8.8* | 14.4 | 5.8* | 15.3 | 6.7* | 8.2 | 3.4* |
| Total number (age 12–23 months) | 609 | 894 | 911 | 924 | 237 | 517 | 491 | 808 | 752 | 778 | 579 | 967 |
| Cryptosporidium (%) | 12.3 | 5.0* | 9.4 | 6.9* | 16.5 | 9.9* | 11.0 | 4.8* | 14.4 | 8.2* | 6.0 | 3.3* |
| Total number (age 24–59 months) | 243 | 503 | 845 | 863 | 137 | 279 | 458 | 744 | 477 | 923 | 463 | 1111 |
| Cryptosporidium (%) | 3.7 | 2.2 | 3.9 | 3.0 | 6.6 | 6.8 | 4.8 | 1.7* | 9.6 | 12.0 | 4.5 | 5.3 |

| LSD           | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls | Cases | Controls |
|---------------|-------|----------|-------|----------|-------|----------|-------|----------|-------|----------|-------|----------|
| Total number (age 0–11 months) | 220 | 259 | 236 | 236 | 155 | 154 | NA | NA | 213 | 213 | 183 | 366 |
| Cryptosporidium (%) | 13.6 | 5.4* | 9.3 | 6.8 | 16.1 | 10.4 | 7.5 | 1.9* | 4.4 | 1.9 | 9.3 | 3.1* |
| Total number (age 12–23 months) | 202 | 273 | 226 | 227 | 175 | 175 | NA | NA | 180 | 194 | 148 | 296 |
| Cryptosporidium (%) | 11.9 | 4.8* | 11.1 | 5.7* | 15.4 | 6.3* | 5.6 | 1.0* | 3.4 | 2.0 | 10.5 | 6.8 |
| Total number (age 24–59 months) | 135 | 250 | 230 | 230 | 101 | 101 | NA | NA | 181 | 187 | 83 | 248 |
| Cryptosporidium (%) | 7.4 | 3.6 | 4.3 | 2.6 | 9.9 | 3.0 | 3.3 | 1.6 | 3.6 | 2.0 | 5.6 | 1.4* |

* P < 0.05 for the difference between cases and controls, as obtained in unadjusted conditional logistic regression models.

MSD: moderate-to-severe diarrhea, LSD: less severe diarrhea, EIA: enzyme immune assay, NA: not applicable, the Kenyan site did not enroll LSD cases in the GEMS-1A component

Mozambique this was found only in the toddler age group and in Pakistan only in infants and in children age 24–59 months (Table 1). Adjusted attributable incidence rates of Cryptosporidium LSD by site and age group are shown in Table 2.

When MSD data were examined in narrower age groups, we found significant positive associations between Cryptosporidium and MSD at 4 sites (Mali, Mozambique, Kenya, India) in the first 5 months of life. ORs were higher at age 6–11 months, except in Mali. A significant OR between Cryptosporidium and MSD was observed in Mali, Mozambique, Kenya and India at ages 0–17 months. In Gambia and Pakistan, this association was significant from 6–23 months of age and in Bangladesh only at age 6–11 months. Adjusted AFs increased from age 0–5 months to age 6–11 months and were highest at age 6–11 months, except in Pakistan (Table 3).

**Cryptosporidium species**

We identified Cryptosporidium species by PCR testing for 18S and Lib13 targets in a random subset of 3,809 case/control pairs. Samples with unresolved species by Lib13 (which only differentiates *C. hominis* from *C. parvum*) had species investigated by 18S and GP60 assays, as described in the Methods. This revealed 338 EIA+/PCR+ cases and 157 EIA+/PCR+ controls. Among the 338 samples from Cryptosporidium-positive MSD cases, 333 were suitable for further testing, of which 259 (77.8%), 33 (9.9%), 4 (1.2%), and 2 (0.6%), respectively, were positive for *C. hominis, C. parvum*, both *C. hominis* and *C. parvum* and *C. meleagris*; the species of 35 (10.5%) specimens remained undetermined. Corresponding percentages in controls were 68.2%, 8.9%, 0.6%, 0.6%, and 21.0%. The species of one control sample (0.6%) was identified as *C. canis*. GP60 subtypes were identified on 71 EIA+/PCR+ specimens including 32 *C. hominis*, 37 *C. parvum*, and 2 *C. meleagris*. Of 37 *C. parvum* infections, 34 (91.9%) were anthroponotic...
strains: 21 were IIc (19 A5G3 and 2 A4G3); 13 were IIe (1 IIeA6G1, 2 IIeA7G1, 7 IIeA10G1, 2 IIeA11, 1 IIeA15); all three non-anthropootic strains were IIdA15G1. These derived from Mali (n = 13), Kenya (n = 9), Mozambique (n = 5), Pakistan (n = 7 including the 3 non-anthropootic types), Bangladesh (n = 2), and Gambia (n = 1). Samples from Kenya and Mozambique were mostly IIcA5G3 (12/14). Mali’s strains were diverse; containing 10/11 IIe strains as well as 3 IIcA5G3. The C. hominis subtypes included Ia (1 A18R2, 1 A19R2, 1 A23R2, 1 A24G1R2, 2 A25R2, 1 A26R2), Ib (3 A9G3, 8 A13G3), Id (1A14), If (exclusively 10 A11G3T3), and If (2 A14G1). Both C. meleagridis were subtyped as IIdA6R1.

### Disease burden

The *Cryptosporidium*-attributable MSD incidence was estimated to be 3.48 (95% CI, 2.27–4.67) and 3.18 (95% CI, 1.85–4.52) per 100 child-years in the African and Asian sites, respectively, in the 0–11 months age group. The respective incidences for toddlers aged 12–23 months were 1.41 (95% CI, 0.73–2.08) and 1.36 (95% CI, 0.66–2.05) per 100 child-years. Corresponding *Cryptosporidium*-attributable LSD incidence rates were 2.52 (95% CI, 0.33–5.01) and 2.52 (95% CI, 0.33–5.01) per 100 child-years.

---

**Table 2. Adjusted attributable incidence (per 100 child-years) and 95% confidence intervals (CIs) of Cryptosporidium-attributable LSD, by site and age group*.**

| Site/age group (months) | Adjusted attributable incidence rate per 100 child-years (95% CI) |
|-------------------------|---------------------------------------------------------------|
| **Gambia**              |                                                               |
| 0–11                    | 4.58 (-0.01–9.53)                                             |
| 12–23                   | 3.49 (-0.01–6.98)                                             |
| 24–59                   | 0.39 (-0.15–0.92)                                             |
| **Mali**                |                                                               |
| 0–11                    | -                                                             |
| 12–23                   | 3.92 (-3.10–10.95)                                            |
| 24–59                   | -                                                             |
| **Mozambique**          |                                                               |
| 0–11                    | 5.36 (-4.90–15.62)                                            |
| 12–23                   | 5.47 (-1.32–12.26)                                            |
| 24–59                   | -                                                             |
| **India**               |                                                               |
| 0–11                    | 4.73 (0.61–8.86)                                              |
| 12–23                   | 3.43 (-0.78–7.64)                                             |
| 24–59                   | -                                                             |
| **Bangladesh**          |                                                               |
| 0–11                    | -                                                             |
| 12–23                   | -                                                             |
| 24–59                   | -                                                             |
| **Pakistan**            |                                                               |
| 0–11                    | 8.46 (-0.03–16.95)                                            |
| 12–23                   | 10.81 (-1.19–22.81)                                           |
| 24–59                   | 0.93 (-0.24–2.09)                                             |

*Weighted adjusted attributable incidence rates were calculated only for site/age groups in which *Cryptosporidium* was associated with LSD with P<0.1 in multivariable conditional logistic regression models that adjusted for the presence of other enteric pathogens.

Note—LSD cases were not enrolled in Kenya during GEMS-1A

doi:10.1371/journal.pntd.0004729.t002
Table 3. Association between Cryptosporidium (by EIA) and MSD from age 0–23 months by site during four years of surveillance: matched unadjusted and adjusted odds ratios (ORs) and adjusted attributable fractions (AF) with 95% confidence intervals (CI)*.

| Site and age group (months) | Number of MSD cases | Number (%) of cases positive for Cryptosporidium | Number of controls | Number (%) of controls positive for Cryptosporidium | Unadjusted OR (95% CI) | P1 | Adjusted OR (95% CI) | P2 | Adjusted AF (95% CI) |
|-----------------------------|----------------------|-----------------------------------------------|-------------------|-----------------------------------------------|----------------------|----|----------------------|----|----------------------|
| Gambia                      |                      |                                               |                   |                                               |                      |    |                      |    |                      |
| <6                          | 86                   | 7 (8.1)                                       | 123               | 6 (4.9)                                       | 1.60 (0.50–5.18)     | 0.43| 1.99 (0.58–6.82)     | 0.28| 4.0 (3.0–11.1)       |
| 6–11                        | 434                  | 76 (17.5)                                     | 660               | 43 (6.5)                                      | 4.00 (2.47–6.47)     | <0.0001| 4.41 (2.65–7.35)     | <0.0001| 13.5 (9.3–17.8)      |
| 12–17                       | 338                  | 45 (13.3)                                     | 478               | 25 (5.2)                                      | 2.87 (1.62–5.08)     | 0.0003| 2.61 (1.38–4.92)     | 0.003| 8.2 (3.5–13.0)       |
| 18–23                       | 271                  | 30 (11.1)                                     | 416               | 20 (4.8)                                      | 2.48 (1.34–4.61)     | 0.004| 3.23 (1.59–6.53)     | 0.001| 7.6 (3.1–12.2)       |
| Mali                        |                      |                                               |                   |                                               |                      |    |                      |    |                      |
| <6                          | 230                  | 26 (11.3)                                     | 230               | 4 (1.7)                                       | 7.29 (2.34–22.71)    | 0.0006| 6.59 (2.07–20.95)    | 0.001| 9.6 (5.1–14.1)       |
| 6–11                        | 731                  | 134 (18.3)                                    | 731               | 62 (8.5)                                      | 2.58 (1.83–3.64)     | <0.0001| 3.76 (2.48–5.70) (Giardia absent) 1 1.24 (0.56–2.77) (Giardia present) 2 | <0.0001| 0.59| 12.3 (8.7–15.8)      |
| 12–17                       | 527                  | 60 (11.4)                                     | 533               | 40 (7.5)                                      | 1.70 (1.07–2.71)     | 0.025| 1.81 (1.10–2.98)     | 0.019| 5.1 (1.1–9.1)        |
| 18–23                       | 384                  | 26 (6.8)                                      | 391               | 24 (6.1)                                      | 1.10 (0.60–2.01)     | 0.76| 1.06 (0.56–2.02)     | 0.85| 0.4 (-3.9–4.7)       |
| Mozambique                  |                      |                                               |                   |                                               |                      |    |                      |   |                      |
| <6                          | 153                  | 22 (14.4)                                     | 293               | 26 (8.9)                                      | 2.29 (1.18–4.43)     | 0.014| 2.41 (1.17–4.98)     | 0.018| 8.4 (2.0–14.8)       |
| 6–11                        | 286                  | 65 (22.7)                                     | 589               | 52 (8.8)                                      | 3.67 (2.32–5.83)     | <0.0001| 5.71 (3.32–9.82)     | <0.0001| 18.7 (13.2–24.3)     |
| 12–17                       | 155                  | 28 (18.1)                                     | 330               | 32 (9.7)                                      | 2.45 (1.35–4.42)     | 0.003| 2.30 (1.19–4.44)     | 0.013| 10.2 (2.7–17.8)      |
| 18–23                       | 82                   | 11 (13.4)                                     | 187               | 19 (10.2)                                     | 1.70 (0.74–3.91)     | 0.21| 1.80 (0.70–4.63)     | 0.22| 6.0 (-4.0–16.0)      |
| Kenya                       |                      |                                               |                   |                                               |                      |    |                      |   |                      |
| <6                          | 306                  | 37 (12.1)                                     | 329               | 17 (5.2)                                      | 2.44 (1.33–4.46)     | 0.004| 3.09 (1.55–6.16)     | 0.001| 8.2 (3.7–12.7)       |
| 6–11                        | 523                  | 82 (15.7)                                     | 567               | 35 (6.2)                                      | 2.79 (1.81–4.31)     | <0.0001| 3.31 (2.08–5.27)     | <0.0001| 10.9 (7.2–14.7)      |
| 12–17                       | 313                  | 38 (12.1)                                     | 516               | 26 (5.0)                                      | 3.06 (1.75–5.37)     | <0.0001| 3.75 (2.02–6.95)     | <0.0001| 8.9 (4.7–13.1)       |
| 18–23                       | 178                  | 16 (9.0)                                      | 292               | 13 (4.5)                                      | 2.29 (1.02–5.17)     | 0.045| 2.43 (1.01–5.86)     | 0.048| 5.3 (-0.1–10.7)      |
| India                       |                      |                                               |                   |                                               |                      |   |                      |   |                      |
| <6                          | 298                  | 45 (15.1)                                     | 301               | 22 (7.3)                                      | 2.35 (1.33–4.13)     | 0.003| 2.44 (1.34–4.44)     | 0.003| 8.9 (3.5–14.3)       |
| 6–11                        | 580                  | 89 (15.3)                                     | 591               | 38 (6.4)                                      | 2.97 (1.91–4.63)     | <0.0001| 3.22 (1.90–5.47)     | <0.0001| 10.6 (6.6–14.6)      |
| 12–17                       | 458                  | 65 (14.2)                                     | 473               | 33 (7.0)                                      | 2.20 (1.40–3.47)     | 0.0007| 2.19 (1.23–3.87)     | 0.007| 7.7 (2.9–12.5)       |
| 18–23                       | 294                  | 43 (14.6)                                     | 305               | 31 (10.2)                                     | 1.59 (0.91–2.77)     | 0.11| 2.09 (0.99–4.40)     | 0.054| 7.6 (0.9–14.3)       |

(Continued)
Applying these incidence rates to the pediatric population age <2 years in the SSA and I/P/B/N/A regions, respectively, yielded annual estimated Cryptosporidium MSD burdens of ~1.2 million and ~1.5 million cases. The total number of LSD and MSD cases was estimated to be 2.9 million in this age group in SSA and 4.7 million in the populous I/P/B/N/A region (Table 4). The proportions of cases due to *C. hominis* and *C. parvum* in the subset tested for species were multiplied by the total estimated number of Cryptosporidium-attributable diarrhea cases in both regions (~7.6 million), yielding estimates of 5.9 million *C. hominis*, 0.76 million *C. parvum* and 90,000 thousand co-infected (*C. hominis* plus *C. parvum*) cases in children aged <2 years.
Table 4. Estimated number (in thousands) of diarrhea cases attributable to Cryptosporidium by age, country and region\(^5\).

| Syndrome/age (months) | Gambia | Mali | Mozambique | Kenya\(^\ast\) | India | Bangladesh | Pakistan | Sub-Saharan Africa\(^1\) | South Asia \(^*\) |
|-----------------------|--------|------|------------|----------------|-------|------------|----------|--------------------------|------------------|
| **MSD**               |        |      |            |                |       |            |          |                          |                  |
| Age 0–11              |        |      |            |                |       |            |          |                          |                  |
| Number (2.5\(^{th}\)– | 2.0 (1.4– | 17.2 (12.0– | 28.5 (19.9– | 44.4 (31.1– | 784.5 (518.0– | 100.9 (66.6– | 129.6 (85.5– | 880.5 (616.3– | 1,068.0 (705.5– |
| 97.5\(^{th}\) percentile) | 2.9)   | 25.1) | 41.5)      | 64.8)          | 1,263.3) | 162.6)     | 209.0)   | 1,283.3)     | 1,719.3)        |
| Age 12–23             |        |      |            |                |       |            |          |                          |                  |
| Number (2.5\(^{th}\)– | 0.8 (0.5– | 7.0 (4.1– | 11.6 (6.8– | 18.8 (10.6– | 334.7 (187.0– | 43.0 (24.0– | 55.3 (30.8– | 357.2 (210.2– | 455.7 (254.6– |
| 97.5\(^{th}\) percentile) | 1.4)   | 11.9) | 19.7)      | 30.8)          | 576.0) | 74.1)      | 95.2)    | 610.2)       | 784.1)           |
| Age 0–23              |        |      |            |                |       |            |          |                          |                  |
| Number (2.5\(^{th}\)– | 2.8 (2.1– | 24.8 (17.7– | 41.1 (29.5– | 64.2 (46.0– | 1,119.2 (791.7– | 143.9 (101.7– | 184.8 (130.0– | 1,237.0 (910.5– | 1,523.8 (1,078.1– |
| 97.5\(^{th}\) percentile) | 3.8)   | 32.7) | 54.0)      | 84.3)          | 1,596.6) | 205.5)     | 264.0)   | 1,671.1)     | 2,172.9)         |
| **LSD**               |        |      |            |                |       |            |          |                          |                  |
| Age 0–11              |        |      |            |                |       |            |          |                          |                  |
| Number (2.5\(^{th}\)– | 1.5 (0.2– | 12.5 (1.4– | 20.7 (2.3– | 32.3 (3.6– | 1,201.7 (314.2– | 154.5 (40.3– | 198.5 (51.7– | 639.3 (71.9– | 1,636.1 (427.4– |
| 97.5\(^{th}\) percentile) | 4.0)   | 34.4) | 57.0)      | 88.9)          | 2,469.2) | 317.4)     | 407.6)   | 796.4)       | 3,361.4)         |
| Age 12–23             |        |      |            |                |       |            |          |                          |                  |
| Number (2.5\(^{th}\)– | 2.3 (1.5– | 20.0 (12.6– | 33.1 (20.7– | 51.6 (32.4– | 1,162.1 (219.9– | 149.4 (28.3– | 191.9 (36.3– | 1,023.0 (642.1– | 1,582.1 (299.5– |
| 97.5\(^{th}\) percentile) | 9.5)   | 81.8) | 135.7)     | 211.6)         | 2,687.4) | 345.6)     | 443.8)   | 1,192.8)     | 3,658.1)         |
| Age 0–23              |        |      |            |                |       |            |          |                          |                  |
| Number (2.5\(^{th}\)– | 3.8 (-0.7– | 32.5 (1.6– | 53.8 (-10.6– | 83.9 (16.6– | 2,363.8 (1,028.5– | 303.9 (132.2– | 390.4 (169.7– | 1,662.6 (710.8– | 3,218.2 (5,451.8– |
| 97.5\(^{th}\) percentile) | 12.4) | 106.6) | 176.4)     | 275.1)         | 4,301.3) | 553.0)     | 710.8)   | 5,541.8)     | 5,855.6)         |
| **MSD & LSD**         |        |      |            |                |       |            |          |                          |                  |
| Age 0–11              |        |      |            |                |       |            |          |                          |                  |
| Number (2.5\(^{th}\)– | 3.5 (1.8– | 29.7 (15.8– | 49.2 (26.3– | 76.7 (40.9– | 1,986.3 (1,066.4– | 255.4 (137.1– | 328.0 (176.0– | 1,519.8 (811.0– | 2,704.1 (1,451.9– |
| 97.5\(^{th}\) percentile) | 6.0)   | 52.0) | 86.0)      | 134.1)         | 3,334.7) | 428.8)     | 551.0)   | 2,657.7)     | 4,540.0)         |
| Age 12–23             |        |      |            |                |       |            |          |                          |                  |
| Number (2.5\(^{th}\)– | 3.1 (-1.0– | 26.9 (-8.2– | 44.6 (-13.6– | 69.7 (-21.3– | 1,496.8 (545.5– | 192.5 (70.1– | 247.2 (90.1– | 1,380.5 (421.6– | 2,037.8 (742.6– |
| 97.5\(^{th}\) percentile) | 10.2) | 87.5) | 144.9)     | 226.1)         | 3,046.4) | 391.4)     | 502.9)   | 4,479.7)     | 4,147.8)         |
| Age 0–23              |        |      |            |                |       |            |          |                          |                  |
| Number (2.5\(^{th}\)– | 6.6 (1.8– | 56.6 (15.6– | 93.8 (25.9– | 146.4 (40.4– | 3,483.1 (2,118.7– | 447.8 (271.5– | 575.2 (348.6– | 2,900.3 (800.6– | 4,741.9 (2,874.8– |
| 97.5\(^{th}\) percentile) | 15.0) | 128.5) | 212.4)     | 331.8)         | 5,481.1) | 705.3)     | 906.1)   | 6,575.0)     | 7,462.5)         |

\(^1\) Countries and areas included in the extrapolations to sub-Saharan Africa region: Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d’Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mayotte, Mozambique, Namibia, Niger, Nigeria, Réunion, Rwanda, Saint Helena, São Tomé and Príncipe, Senegal, Seychelles, Sierra Leone, Somalia, Sudan, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia, and Zimbabwe [29].

\(^*\) Extrapolation was made to the most populous countries in South Asia: India, Bangladesh, Pakistan, Afghanistan and Nepal [29].

\(^5\) Data presented are estimated absolute numbers of cases attributable to Cryptosporidium, in parentheses are the 2.5\(^{th}\) and 97.5\(^{th}\) percentiles (corresponding to 95\% confidence intervals), which were estimated by Monte Carlo simulations

** Extrapolation of the combined incidence rate of the 3 African sites of GEMS-1A (Gambia, Mali, Mozambique) was made to the population of Kenya.

doi:10.1371/journal.pntd.0004729.t004
Cryptosporidium-attributable deaths among Cryptosporidium-positive diarrhea cases in the population and all diarrhea-attributable deaths

Subtracting the EFR among all controls of MSD cases aged <24 months at African sites (37/6258, 0.6%) from the ECFR among Cryptosporidium-positive MSD cases (41/643, 6.4%) (Table 5) yielded a Cryptosporidium-attributable ECFR of 5.8% (95% CI, 4.4%–7.6%). Similarly, subtracting the EFR in controls of LSD cases aged <24 months at African sites (4/1261, 0.3%) from the ECFR among Cryptosporidium-positive LSD cases (1/139, 0.7%) produced an estimated Cryptosporidium-attributable ECFR of 0.4% (95% CI, -0.4%–3.7%). Multiplying these Cryptosporidium-attributable ECFRs by the numbers of Cryptosporidium-positive cases generated estimates of 107,000 Cryptosporidium-attributable MSD deaths (95% CI, 68,200–151,000) and 16,300 Cryptosporidium-attributable LSD deaths (95% CI, 0–75,200) in the SSA region. After subtracting the EFR in controls of MSD and LSD cases at Asian sites (6/6758, 0.09%) from the ECFR among Cryptosporidium-positive MSD and LSD cases combined (5/523, 1.0%) in the Asian sites and multiplying the resultant Cryptosporidium-attributable ECFR of 0.9% (95% CI, 0.4%–1.9%) by all Cryptosporidium-positive diarrhea cases, we estimate 78,900 (95% CI, 0–159,000) deaths attributable to Cryptosporidium-positive diarrhea in the (I/P/B/N/A) region. Thus, we estimate a total of ~202,000 Cryptosporidium-attributable diarrhea deaths in the two regions combined. Using the same methodology, we estimate 455,000 (95% CI, 280,000–630,000) annual diarrhea-attributable deaths in the SSA region and 254,000 (95% CI, 13,900–494,000) in the (I/P/B/N/A) region.

Table 5. Extended fatality risk during ~60 days following the onset of acute diarrhea among cases and controls aged 0–23 months*.

| Group                        | African sites | Asian sites |
|------------------------------|---------------|-------------|
|                              | Total subjects | No. of deaths during ~60 days of follow-up | Percent (95% CI) | Total subjects | No. of deaths during ~60 days of follow-up | Percent (95% CI) |
| Total MSD cases              | 4552          | 169         | 3.7% (3.2%-4.3%) | 3828          | 26          | 0.7% (0.4%-1.0%) |
| Cryptosporidium-positive MSD cases | 643          | 41          | 6.4% (4.6%-8.6%) | 451           | 4           | 0.9% (0.2%-2.3%) |
| Cryptosporidium-negative MSD cases | 3909         | 128         | 3.3% (2.7%-3.9%) | 3377          | 22          | 0.7% (0.4%-1.0%) |
| All controls of MSD cases    | 6258          | 37          | 0.6% (0.4%-0.8%) | 5204          | 3           | 0.06% (0.01%-0.2%) |
| Controls of Cryptosporidium-positive MSD cases | 928          | 4           | 0.4% (0.1%-1.1%) | 573           | 0           | 0.0% (0.0%-0.6%) |
| Total LSD cases              | 1139          | 6           | 0.5% (0.2%-1.1%) | 1035          | 5           | 0.5% (0.2%-1.1%) |
| Cryptosporidium-positive LSD cases | 139          | 1           | 0.7% (0.1%-3.9%) | 72            | 1           | 1.4% (0.3%-7.5%) |
| Cryptosporidium-negative LSD cases | 1000         | 5           | 0.5% (0.2%-1.1%) | 963           | 4           | 0.4% (0.2%-1.1%) |
| All controls of LSD cases    | 1261          | 4           | 0.3% (0.1%-0.8%) | 1554          | 3           | 0.2% (0.07%-0.5%) |
| Controls of Cryptosporidium-positive LSD cases | 156          | 1           | 0.6% (0.02%-3.5%) | 102           | 0           | 0.0% (0.0%-3.6%) |

* MSD: moderate-to-severe diarrhea (GEMS-1 and GEMS-1A data), LSD: less severe diarrhea (GEMS-1A data). This table includes data only for cases with Cryptosporidium results and non-missing data on vital status at follow-up, and their matched controls.

doi:10.1371/journal.pntd.0004729.t005
Excess deaths among *Cryptosporidium*-attributable MSD and LSD cases

Subtracting the ECFR of *Cryptosporidium*-negative MSD cases (3.3%) from the ECFR of *Cryptosporidium*-positive MSD cases (6.4%) (Table 5) and multiplying the result by the number of *Cryptosporidium*-attributable MSD cases in the SSA region indicated that *Cryptosporidium* was responsible for an excess ~38,400 (95% CI, 13,400–68,100) MSD deaths among *Cryptosporidium*-attributable MSD cases. The analogous calculations based on LSD data (Table 5) suggested that *Cryptosporidium* led to ~3,600 (95% CI, -31,600–46,000) excess LSD deaths per year. In Asian sites the estimate of annual excess deaths in children <24 months of age with *Cryptosporidium*-attributable diarrhea was ~16,900 (95% CI, -20,900–61,100). Thus, between the two regions we estimate that *Cryptosporidium* was responsible for ~59,000 excess deaths in cases of *Cryptosporidium*-attributable diarrhea in children aged <24 months, compared to the expected deaths in the same number of *Cryptosporidium*-negative cases.

Discussion

There have been few attempts to estimate the burden of *Cryptosporidium* diarrheal disease in large populations. One exception is the *Cryptosporidium* burden estimate published for India [31]. Others are the global *Cryptosporidium*-associated mortality estimates contained within Global Burden of Disease (GBD) and Child Epidemiology Estimation Group (CHERG) reports [32–34]. Three obstacles have heretofore impeded attempts to estimate region-wide *Cryptosporidium* disease burdens, including: 1) marked heterogeneity of clinical and laboratory methods used in studies of the etiology of pediatric diarrhea; 2) failure to take into account that many children without diarrhea also excrete *Cryptosporidium*; 3) a lack of species-specific data from clinical studies which might guide vaccine development efforts. In this paper, we utilized datasets and laboratory tests that allowed these obstacles to be overcome.

GEMS-1, pursued in representative sites in 7 developing countries, documented *Cryptosporidium* as a leading cause of endemic childhood diarrhea of a severity that brings children to healthcare facilities, particularly during the first 24 months of life [10]. Importantly, GEMS-1 utilized rigorous standardized clinical, epidemiologic and laboratory methods to collect extensive data over several consecutive years in 7 sites. By including matched control children without diarrhea and adjusting for mixed infections with other enteropathogens, GEMS-1 quantified the specific role of *Cryptosporidium* in childhood diarrheal disease beyond the background carriage of *Cryptosporidium* [10,23]. Finally, our results represent the first systematic, multisite, geographically-diverse assessment of the species-specific burden of *Cryptosporidium*-associated pediatric diarrhea, unequivocally corroborating the dominance of *C. hominis* [7,35–38] in infants and toddlers at all sites and revealing that 92% of *C. parvum* infections were due to recognized anthroponotic subtypes [39–41].

Despite our cautious extrapolation strategy, we found a substantial disease burden of ~7.6 million diarrhea cases annually attributable to *Cryptosporidium*, including ~2.9 million in SSA and ~4.7 million in the I/P/B/N/A region. Our estimated annual number of *Cryptosporidium*-attributable diarrhea cases (3.5 million) among Indian children aged <24 months falls within the lower limit of the burden estimated by Sarkar *et al.* [31].

GEMS-1 [10] and other studies [8,13,42] have demonstrated a negative impact of *Cryptosporidium*-associated diarrhea on linear growth (stunting), a nutritional insult that increases the risk for severe or fatal outcomes [43,44]. The Malnutrition and Enteric Infections (MAL-ED) study prospectively followed birth cohorts in Peru, Brazil, Tanzania, South Africa, Pakistan, Bangladesh, Nepal and India with twice-weekly household visits through age 24 months [45], thereby detecting mostly mild diarrheal episodes typically not observed in
healthcare facility-based passive surveillance. Thus, MAL-ED provides data on the etiology of milder diarrheal illness and revealed *Cryptosporidium* to be the fifth most important diarrhea-associated pathogen in the first year of life and seventh most important in the second year of life [45]. Regional burden estimates that we calculated did not incorporate the burden of milder clinical forms of *Cryptosporidium*-associated illness detected by active-surveillance household visits, as in MAL-ED, and thus probably under-estimates total burden.

The two models of the death burden in children with *Cryptosporidium* described in this manuscript demonstrated that among the 4 African sites MSD cases infected with *Cryptosporidium* at enrollment had a significantly increased ECFR during the subsequent ~60-days [10] compared to the risk of death in controls and to the risk of death in *Cryptosporidium*-negative diarrhea cases. ECFR in children with *Cryptosporidium* in the African sites was particularly driven by Mozambique (high HIV prevalence) and rural Gambia (low HIV), suggesting that factors other than HIV infection, such as malnutrition, play a role in *Cryptosporidium*-related deaths in SSA. While overall mortality during the 60-day follow-up was much lower in the Asian sites [10], nevertheless our estimates indicate a substantial *Cryptosporidium*-related death burden because of the enormity of the <2 years population. Our GEMS-based estimates of deaths under 24 months attributable to *Cryptosporidium* diarrhea are greater than the estimates reported by GBD (35,200 deaths) [33] and CHERG (12,000) [34] among children age <5 years. Discrepancies between GBD and CHERG estimates of <5 years diarrheal disease mortality are recognized [18,46,47]. Our estimates of total diarrhea-attributable deaths (455,000 and 254,000 in the SSA and I/P/B/N/A regions, respectively) are somewhat larger than estimates for children <5 years of age for 2011 in a recent review [48]. In large part these differences are likely because the GEMS estimates are uniquely based on follow-up information on deaths among laboratory-diagnosed *Cryptosporidium*-associated diarrhea cases, whereas CHERG and GBD estimates are based on deaths that occur acutely.

Our observational study design does not permit definitive determination of the direct causation between *Cryptosporidium*-positivity and deaths in young children. Nonetheless, the GEMS-based findings corroborate other results from West Africa [9] highlighting *Cryptosporidium* as a very clear strong signal for children at increased risk for death. From a public health perspective, this is sufficient to plan interventions aimed at reducing the risk of death in such high-risk groups.

We observed a general age-specific pattern of *Cryptosporidium* infection and a strong association with MSD, with documentation of exposure in the first few months of life (in both cases and controls), a peak adjusted Attributable Fraction at age 6–11 months and a decrease thereafter (Table 3). We interpret this as reflecting a time-limited (first 5 months of life), passive protection mediated by maternally-transferred serum IgG as well as secretory IgA antibodies and other protective components of breast milk, despite exposure to the pathogen. Over the first two years of life, the prevalence of *Cryptosporidium* positivity in the controls remains impressively static documenting continuing exposure. However, beginning at ~6 months of age, clinical episodes of *Cryptosporidium*-associated diarrheal illness become more common and continue through age 23 months. By ~24 months of age these clinical and subclinical infections appear to induce in most toddlers acquired active immunity against further *Cryptosporidium* clinical illness. Support for this interpretation comes from a cohort study of Bedouin children in Southern Israel, a population under transition [49]. Serum IgG and IgM antibodies to a *Cryptosporidium* oocyst lysate were measured in children ranging from neonates to toddlers age 23 months [49]. High geometric mean titers (GMT) of serum IgG antibodies (of presumed maternal origin) were recorded at birth. GMT then decreased gradually until age 6 months, after which it increased progressively, as did the incidence of diarrheal illness and detection of *Cryptosporidium* in stools [49]. Collectively, these observations can be interpreted
as indicating that immunity against Cryptosporidium develops following natural exposure to the pathogen. Measurements of serum anti-gp15 antibody and clinical and sub-clinical infections were also monitored in a cohort of infants and toddlers in Vellore, India. Children who lacked anti-gp15 antibodies just before weaning had higher rates of Cryptosporidium infections (77%) than seropositive children (59%), although with the relatively small numbers in the cohort the difference did not reach statistical significance (p = 0.076) [50].

Studies of infection-derived immunity in gnotobiotic piglets further support the notion of acquired immunity to C. hominis, as an initial induced C. hominis gastroenteritis in piglets significantly protected them against subsequent re-challenge with C. hominis [51]. Our documentation of the predominance of C. hominis over C. parvum as a pathogen for human infants implies that vaccine development research should prioritize protection against this species and against anthropogenic (human host-restricted) subtypes of C. parvum. The lower incidence of Cryptosporidium disease in infants <6 months old provides a window wherein multiple spaced doses of a future vaccine administered to infants may elicit protection for the subsequent increased risk of clinical Cryptosporidium disease encountered from age 6 to 23 months.

Our study has three obvious limitations. While we have extensive data on MSD cases from 7 sites over 4 years, we have only 1-year enrollment of LSD cases from 6 sites. Thus, estimates on children with LSD are less robust than for MSD. Second, we generated pooled estimates of disease incidence and mortality for SSA and I/P/B/N/A and assumed each to be representative of those regions. However, until locally-representative, standardized data become available, our approach is warranted. That Cryptosporidium appeared important as a pathogen in both urban and rural, high and low HIV settings, provides evidence that broad extrapolation is justified. Third, the species of a small fraction of Cryptosporidium-positive specimens remained unresolved because, although they were positive by EIA and PCR, we could not amplify the long fragments of DNA necessary for species-specific sequence determination of samples mostly with lower parasite load (average 18S PCR Ct 30±4 versus 21±5 for speciated samples, Mann-Whitney U test P<0.001). That said, non-hominis/non-parvum species appeared to be quite rare. As for the species, the anthropogenic IIc and Ile were predominant C. parvum subtype families in this study with a larger portion of Ile than often appreciated [39]. Similar findings on C. parvum subtypes have been described in India [36]. Of 32 C. hominis infections with GP60 typing data, the predominant subtype families were Ia, Ib, and Ie. Ia had more diverse subtypes [40,52], while le subtype was exclusively A11G3T3, consistent with previous reports [36,39]. IbA13G3 infections appear to be common in West Africa. We found these in Mali (n = 4, 2 in cases) and Gambia (n = 4, all in cases), consistent with the high proportions previously seen in Ghana [40]. The observation that the C. parvum parasites associated with MSD of young children in developing countries represent a restricted anthropogenic subset of all C. parvum is important as it enhances our ability to better understand the epidemiology of cryptosporidiosis and helps direct our vaccine development efforts.

Currently, there is little research to develop Cryptosporidium vaccines for humans and only one licensed drug, nitazoxanide, to ameliorate Cryptosporidium diarrhea in children [53]. However, nitazoxanide is currently not recommended for use in infants <12 months of age, exhibits little efficacy in HIV-infected hosts and evidence of efficacy from controlled pediatric trials is limited [53]. The sizable case and death burden of Cryptosporidium in the SSA and I/P/B/N/A regions where ~80% of global deaths among young children occur calls for governments, global policymakers, and funding agencies to invest in developing new tools (e.g., vaccines) to prevent Cryptosporidium diarrheal illness and improved methods to diagnose and treat it, while also advocating increased access to improved sanitation and safe water.
Acknowledgments

We thank the families who participated in these studies and the project field and laboratory staff for their professionalism and dedication. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

Author Contributions

Conceived and designed the experiments: SOS KM KLK JPN MML. Performed the experiments: SOS DN THF SP DSu AKMZ ASGF DSah RA PLA RFB QB BT DSan UO BM TR SK SAh SQ FQ AH SKD MA MJH IM TN SAc RO JBO JOO EDM CEO LYB SL SMT RMRB JL JZ ERH. Analyzed the data: KM DN THF YW WCB TZB VM. Contributed reagents/materials/analysis tools: JL JZ ERH. Wrote the paper: SOS KM KLK JPN HS JL ERH MML.

References

1. Shirley DA, Moonah SN, Kotloff KL. Burden of disease from cryptosporidiosis. Curr Opin Infect Dis 2012 Oct; 25(5):555–63. doi: 10.1097/QCO.0b013e328357e569 PMID: 22907279
2. Chappell CL, Okhuysen PC. Cryptosporidiosis. Curr Opin Infect Dis 2002 Oct; 15(5):523–7. PMID: 12686887
3. Snelling WJ, Xiao L, Ortega-Pierres G, Lowery CJ, Moore JE, Rao JR, et al. Cryptosporidiosis in developing countries. J Infect Dev Ctries 2007 Dec 1; 1(3):246–52. PMID: 19734601
4. Checkley W, White AC Jr., Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis 2015 Jan; 15(1):85–94. doi: 10.1016/S1473-3099(14)70772-8 PMID: 25278220
5. Mac Kenzie WR, Hoxie NJ, Proctor ME, Gradus MS, Blair KA, Peterson DE, et al. A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply. N Engl J Med 1994 Jul 21; 331(3):161–7. PMID: 7818640
6. Johansen OH, Hanevik K, Thrana F, Carlson A, Stachurska-Hagen T, Skaare D, et al. Symptomatic and asymptomatic secondary transmission of Cryptosporidium parvum following two related outbreaks in schoolchildren. Epidemiol Infect 2015 Jun; 143(8):1702–9. doi: 10.1017/S095026881400243X PMID: 25268811
7. Haque R, Mondal D, Karim A, Molla IH, Rahim A, Faruque AS, et al. Prospective case-control study of the association between common enteric protozoal parasites and diarrhoea in Bangladesh. Clin Infect Dis 2009 May 1; 48(9):1191–7. doi: 10.1086/597580 PMID: 19323634
8. Molbak K, Andersen M, Aaby P, Hojlyng N, Gottschau A, Sa JC, Ingholt L, da Silva AP, et al. Cryptosporidiosis in infancy and childhood mortality in Guinea Bissau, west Africa. Am J Clin Nutr 1997 Jan; 65(1):149–52. PMID: 8988927
9. Molbak K, Hojlyng N, Gottschau A, Sa JC, Ingholt L, da Silva AP, et al. Cryptosporidiosis in infancy and childhood mortality in Guinea Bissau, west Africa. BMJ 1993 Aug 14; 307(6901):417–20. PMID: 8374453
10. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013 Jul;20; 382(9888):209–22. doi: 10.1016/S0140-6736(13)60844-2 PMID: 23680352
11. Newman RD, Sears CL, Moore SR, Nataro JP, Wuhib T, Agnew DA, et al. Longitudinal study of Cryptosporidium infection in children in northeastern Brazil. J Infect Dis 1999 Jul; 180(1):167–75. PMID: 10353875
12. Newman RD, Zu SX, Wuhib T, Lima AA, Guerrant RL, Sears CL. Household epidemiology of Cryptosporidium parvum infection in an urban community in northeast Brazil. Ann Intern Med 1994 Mar 15; 120(6):500–5. PMID: 8311473
13. Checkley W, Epstein LD, Gilman RH, Black RE, Cabrera L, Sterling CR. Effects of Cryptosporidium parvum infection in Peruvian children: growth faltering and subsequent catch-up growth. Am J Epidemiol 1998 Sep 1; 148(5):497–506. PMID: 9737562
14. Wanyiri JW, Kanyi H, Maina S, Wang DE, Steen A, Ngugi P, et al. Cryptosporidiosis in HIV/AIDS patients in Kenya: clinical features, epidemiology, molecular characterization and antibody responses. Am J Trop Med Hyg 2014 Aug; 91(2):319–29. doi: 10.4269/ajtmh.13-0254 PMID: 24865675
15. Shepherd RC, Reed CL, Sinha GP. Shedding of oocysts of Cryptosporidium in immunocompetent patients. J Clin Pathol 1988 Oct; 41(10):1104–6. PMID: 3192732

16. Chappell CL, Okhuysen PC, Sterling CR, DuPont HL. Cryptosporidium parvum: intensity of infection and oocyst excretion patterns in healthy volunteers. J Infect Dis 1996 Jan; 173(1):232–6. PMID: 8537664

17. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010 Jun 5; 375(9730):1969–87. doi: 10.1016/S0140-6736(10)60549-1 PMID: 20466419

18. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 2015 Jan 31; 385(9966):430–40. doi: 10.1016/S0140-6736(14)61698-6 PMID: 25280870

19. Levine MM, Koloff KL, Nataro JP, Muhsen K. The Global Enteric Multicenter Study (GEMS): Impetus, Rationale, and Genesis. Clin Infect Dis 2012 Dec; 55 Suppl 4:S215–24. doi: 10.1093/cid/cis761.:S215-S224 PMID: 23169934

20. Farag TH, Nasrin D, Wu Y, Muhsen K, Blackwelder WC, Sommerfelt H, et al. Some Epidemiologic, Clinical, Microbiologic, and Organizational Assumptions That Influenced the Design and Performance of the Global Enteric Multicenter Study (GEMS). Clin Infect Dis 2012 Dec; 55 Suppl 4:S225–31. doi: 10.1093/cid/cis787.:S225-S231 PMID: 23169935

21. Koloff KL, Blackwelder WC, Nasrin D, Nataro JP, Farag TH, van EA, et al. The Global Enteric Multicenter Study (GEMS) of Diarrheal Disease in Infants and Young Children in Developing Countries: Epidemiologic and Clinical Methods of the Case/Control Study. Clin Infect Dis 2012 Dec; 55 Suppl 4:S232–45. doi: 10.1093/cid/cis753.:S232-S245 PMID: 23169936

22. Panchalingam S, Antonio M, Hossain A, Mandomando I, Ochieng B, Oundo J, et al. Diagnostic Microbiologic Methods in the GEMS-1 Case/Control Study. Clin Infect Dis 2012 Dec; 55 Suppl 4:S294–302. doi: 10.1093/cid/cis754.:S294-S302 PMID: 23169941

23. Blackwelder WC, Biswas K, Wu Y, Koloff KL, Farag TH, Nasrin D, et al. Statistical Methods in the Global Enteric Multicenter Study (GEMS). Clin Infect Dis 2012 Dec; 55 Suppl 4:S246–53. doi: 10.1093/cid/cis788.:S246-S253 PMID: 23169937

24. Liu J, Kabir F, Manneh J, Lertsethtakarn P, Begum S, Gratz J, et al. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. Lancet Infect Dis 2014 Jul 9;(14: ):10–3099.

25. Hadfield SJ, Robinson G, Elwin K, Chalmers RM. Detection and Differentiation of Cryptosporidium spp. in Human Clinical Samples by Use of Real-Time PCR. J Clin Microbiol 2011 Mar; 49(3):918–24. doi: 10.1128/JCM.01733-10 PMID: 21177904

26. Xiao L, Bern C, Limor J, Sulaiman I, Roberts J, Checkley W, et al. Identification of 5 types of Cryptosporidium parasites in children in Lima, Peru. J Infect Dis 2001 Feb 1; 183(3):492–7. PMID: 11133382

27. Alves M, Xiao L, Sulaiman I, Lai AA, Matos O, Antunes F. Subgenotype analysis of Cryptosporidium isolates from humans, cattle, and zoo ruminants in Portugal. J Clin Microbiol 2003 Jun; 41(6):2744–7. PMID: 12791920

28. Nasrin D, Wu Y, Blackwelder WC, Farag TH, Saha D, Sow SO, et al. Health care seeking for childhood diarrhoea in developing countries: evidence from seven sites in Africa and Asia. Am J Trop Med Hyg 2013 Jul; 89(1 Suppl):3–12. doi: 10.4269/ajtmh.12-0749 PMID: 23629939

29. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2012 revision. United Nations; 2013.

30. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998 Apr 30; 17(8):873–90. PMID: 9595617

31. Sarkar R, Tate JE, Ajampur SS, Kattula D, John J, Ward HD, et al. Burden of diarrhoea, hospitalization and mortality due to cryptosporidial infections in Indian children. PLoS Negl Trop Dis 2014 Jul 24; 8(7): e3042. doi: 10.1371/journal.pntd.0003042 PMID: 25058664

32. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012 Dec 15; 380(9859):2095–128. doi: 10.1016/S0140-6736(12) 61728-0 PMID: 23245604

33. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015 Jan 10; 385(9963):117–71. doi: 10.1016/ S0140-6736(14)61682-2 PMID: 25530442
Lazarus RP, Ajjampur SS, Sarkar R, Geetha JC, Prabakaran AD, Velusamy V, et al. Serum Anti-Cryp-

Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneu-

Robin G, Fraser D, Orr N, Sela T, Slepon R, Ambar R, et al. Cryptosporidium infection in Bedouin infants assessed by prospective evaluation of anticyptosporidial antibodies and stool examination. Am J Epidemiol 2001 Jan 15;153(2):194–201. PMID: 11159166

Lazarus RP, Ajjampur SS, Sarkar R, Geetha JC, Prabakaran AD, Velusamy V, et al. Serum Anti-Cryp-

Sheoran A, Wiffin A, Widger G, Singh P, Tzipori S. Infection with Cryptosporidium hominis provides incomplete protection of the host against Cryptosporidium parvum. J Infect Dis 2012 Mar 15;205 (6):1019–23. doi: 10.1093/infdis/jir874 PMID: 22279124

Molley SF, Smith HV, Kirwan P, Nichols RA, Asaolu SO, Connelly L, et al. Identification of a high diversity of Cryptosporidium species genotypes and subtypes in a pediatric population in Nigeria. Am J Trop Med Hyg 2010 Apr;82(4):608–13. doi: 10.4269/ajtmh.2010.09-0624 PMID: 20348508

46. Liu L, Black RE, Cousins S, Mathers C, Lawn JE, Hogan DR. Causes of child death: comparison of MCEE and GBD 2013 estimates. Lancet 2015 Jun 20;385(9986):2461–2. doi: 10.1016/S0140-6736(15)61132-1 PMID: 26122064

47. Kovacs SD, Mullholland K, Bosch J, Campbell H, Forouzanfar MH, Khalil I, et al. Deconstructing the differences: a comparison of GBD 2010 and CHERG’s approach to estimating the mortality burden of diarrhea, pneumonia, and their etiologies. BMC Infect Dis 2015 Jan 16;15:16. doi: 10.1186/s12879-014-0728-4;16–0728 PMID: 25992774

48. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. Lancet 2013 Apr;20:381(9875):1405–16. doi: 10.1016/S0140-6736(13)60222-6 PMID: 23582636

49. Xiao L. Molecular epidemiology of cryptosporidiosis: an update. Exp Parasitol 2010 Jan;124(1):80–9. doi: 10.1016/j.exppara.2009.03.018 PMID: 19358845

50. Eibach D, Krumkamp R, Al-Emran HM, Sarpong N, Hagen RM, Adu-Sarkodie Y, et al. Molecular char-

51. Borad AJ, Allison GM, Wang D, Ahmed S, Karim MM, Kane AV, et al. Systemic antibody responses to Infection with Cryptosporidium hominis provides protection of the host against Cryptosporidium parvum. J Infect Dis 2012 Mar 15;205 (6):1019–23. doi: 10.1093/infdis/jir874 PMID: 22279124

52. Molloy SF, Smith HV, Kirwan P, Nichols RA, Asaolu SO, Connelly L, et al. Identification of a high diversity of Cryptosporidium species genotypes and subtypes in a pediatric population in Nigeria. Am J Trop Med Hyg 2010 Apr;82(4):608–13. doi: 10.4269/ajtmh.2010.09-0624 PMID: 20348508

53. Robins G, Fraser D, Orr N, Sela T, Slepon R, Ambar R, et al. Cryptosporidium infection in Bedouin infants assessed by prospective evaluation of anticyptosporidial antibodies and stool examination. Am J Epidemiol 2001 Jan 15;153(2):194–201. PMID: 11159166

54. Kovalski D, Mulholland K, Bosch J, Campbell H, Forouzanfar MH, Khalil I, et al. Deconstructing the differences: a comparison of GBD 2010 and CHERG’s approach to estimating the mortality burden of diarrhea, pneumonia, and their etiologies. BMC Infect Dis 2015 Jan 16;15:16. doi: 10.1186/s12879-014-0728-4;16–0728 PMID: 25992774

55. Sheoran A, Wiffin A, Widger G, Singh P, Tzipori S. Infection with Cryptosporidium hominis provides incomplete protection of the host against Cryptosporidium parvum. J Infect Dis 2012 Mar 15;205 (6):1019–23. doi: 10.1093/infdis/jir874 PMID: 22279124

56. Molloy SF, Smith HV, Kirwan P, Nichols RA, Asaolu SO, Connelly L, et al. Identification of a high diversity of Cryptosporidium species genotypes and subtypes in a pediatric population in Nigeria. Am J Trop Med Hyg 2010 Apr;82(4):608–13. doi: 10.4269/ajtmh.2010.09-0624 PMID: 20348508
53. Amadi B, Mwiya M, Sianongo S, Payne L, Watuka A, Katubulushi M, et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect Dis 2009 Dec 2; 9:195-195. doi: 10.1186/1471-2334-9-195 PMID: 19954529